Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014851
Filing Date
2023-08-14
Accepted
2023-08-14 16:11:19
Documents
57
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nbse-20230630x10q.htm   iXBRL 10-Q 1310773
2 EX-31.1 nbse-20230630xex31d1.htm EX-31.1 13479
3 EX-31.2 nbse-20230630xex31d2.htm EX-31.2 13415
4 EX-32.1 nbse-20230630xex32d1.htm EX-32.1 9693
  Complete submission text file 0001558370-23-014851.txt   5461350

Data Files

Seq Description Document Type Size
5 EX-101.SCH nbse-20230630.xsd EX-101.SCH 38283
6 EX-101.CAL nbse-20230630_cal.xml EX-101.CAL 37016
7 EX-101.DEF nbse-20230630_def.xml EX-101.DEF 143674
8 EX-101.LAB nbse-20230630_lab.xml EX-101.LAB 373312
9 EX-101.PRE nbse-20230630_pre.xml EX-101.PRE 266695
51 EXTRACTED XBRL INSTANCE DOCUMENT nbse-20230630x10q_htm.xml XML 924920
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

EIN.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35963 | Film No.: 231170204
SIC: 2834 Pharmaceutical Preparations